Unidad Clínica y de Investigación en Lípidos y Arteriosclerosis, Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Universidad de Zaragoza, CIBERCV, Zaragoza, Spain.
Unidad Clínica y de Investigación en Lípidos y Arteriosclerosis, Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Universidad de Zaragoza, CIBERCV, Zaragoza, Spain.
Atherosclerosis. 2017 Aug;263:92-96. doi: 10.1016/j.atherosclerosis.2017.06.009. Epub 2017 Jun 8.
The effect of LDLc lowering with PCSK9 antibodies on tendon xanthomas (TX) is unknown.
TX was measured in 24 heterozygous familial hypercholesterolemia (HeFH) cases and in 24 HeFH controls with or without PCSK9 inhibitors for at least one year.
Exposure to PCSK9 inhibitors in cases was 2.96 ± 1.33 years. LDLc decreased 80.8 ± 7.66% in cases and 56.9 ± 11.1% in controls. There was a decrease in maximum (-5.03%) and mean (-5.32%) TX in cases but not in controls (+3.97%, +3.16, respectively, p = 0.01). PCSK9 inhibitor treatment was independently associated with TX reduction.
Addition of a PCSK9 inhibitor to statin and ezetimibe resulted in a greater decrease in LDLc and TX after 3 years of treatment.
PCSK9 抗体降低 LDLc 对腱黄瘤（TX）的影响尚不清楚。
在 24 名杂合子家族性高胆固醇血症（HeFH）患者和 24 名 HeFH 对照者中，至少使用 PCSK9 抑制剂治疗了 1 年，对 TX 进行了测量。
在病例中，PCSK9 抑制剂的暴露时间为 2.96±1.33 年。病例组 LDLc 降低 80.8±7.66%，对照组降低 56.9±11.1%。病例组的最大（-5.03%）和平均（-5.32%）TX 均有下降，但对照组无下降（分别为+3.97%和+3.16%，p=0.01）。PCSK9 抑制剂治疗与 TX 减少独立相关。
在他汀类药物和依折麦布治疗的基础上加用 PCSK9 抑制剂，可使 LDLc 和 TX 在 3 年治疗后进一步降低。
